211 related articles for article (PubMed ID: 2686076)
1. Biologic response modifiers in cancer therapy: a review.
Quesada JR
Tex Med; 1989 Nov; 85(11):42-7. PubMed ID: 2686076
[TBL] [Abstract][Full Text] [Related]
2. Biological response modifiers: current use and future prospects in cancer therapy.
Bisht M; Bist SS; Dhasmana DC
Indian J Cancer; 2010; 47(4):443-51. PubMed ID: 21131760
[TBL] [Abstract][Full Text] [Related]
3. Biological therapy of ovarian cancer: current directions.
Bookman MA
Semin Oncol; 1998 Jun; 25(3):381-96. PubMed ID: 9633851
[TBL] [Abstract][Full Text] [Related]
4. Biologic therapy in patients receiving salvage treatment.
Bukowski RM
Semin Oncol; 1994 Aug; 21(4 Suppl 7):96-9. PubMed ID: 8091247
[TBL] [Abstract][Full Text] [Related]
5. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor immunotherapy].
Błoński JZ; Warzocha K
Postepy Hig Med Dosw; 1994; 48(6):701-28. PubMed ID: 7675731
[TBL] [Abstract][Full Text] [Related]
7. Biological Response Modifiers Programme and cancer chemotherapy.
Oldham RK
Int J Tissue React; 1982; 4(3):173-88. PubMed ID: 6183193
[TBL] [Abstract][Full Text] [Related]
8. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
Shen RN; Lu L; Kaiser HE; Broxmeyer HE
In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
[TBL] [Abstract][Full Text] [Related]
9. Design of combination biotherapy studies: future goals and challenges.
Gilewski TA; Golomb HM
Semin Oncol; 1990 Feb; 17(1 Suppl 1):3-10; discussion 38-41. PubMed ID: 1689077
[TBL] [Abstract][Full Text] [Related]
10. Biological response modifiers in cancer therapy.
Gupta S; Kanodia AK
Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
[TBL] [Abstract][Full Text] [Related]
11. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
12. Biologicals and biological response modifiers: fourth modality of cancer treatment.
Oldham RK
Cancer Treat Rep; 1984 Jan; 68(1):221-32. PubMed ID: 6198081
[TBL] [Abstract][Full Text] [Related]
13. Cancer treatment: what's ahead?
Parvez T
J Coll Physicians Surg Pak; 2005 Nov; 15(11):738-45. PubMed ID: 16300718
[TBL] [Abstract][Full Text] [Related]
14. Biologic response modifiers: therapeutic approaches to lymphoproliferative diseases.
Stickney DR; Foon KA
Curr Opin Oncol; 1992 Oct; 4(5):847-55. PubMed ID: 1457499
[TBL] [Abstract][Full Text] [Related]
15. Biological response modifier--immunotherapeutic approaches in pancreatic cancer.
Schmiegel W
Hepatogastroenterology; 1989 Dec; 36(6):456-8. PubMed ID: 2693301
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy.
James G
Rev Invest Clin; 1990 Jul; 42 Suppl():22-7. PubMed ID: 19256128
[TBL] [Abstract][Full Text] [Related]
17. Potential adverse events with biologic response modifiers.
Kong JS; Teuber SS; Gershwin ME
Autoimmun Rev; 2006 Aug; 5(7):471-85. PubMed ID: 16920574
[TBL] [Abstract][Full Text] [Related]
18. Biological response modifiers (BRM), chemotherapy, and activated cytotoxic leukocyte subsets: strategies for rational design of apheresis-based cancer immunotherapies.
Stevenson HC; Klein HG
Prog Clin Biol Res; 1990; 337():559-65. PubMed ID: 2353018
[No Abstract] [Full Text] [Related]
19. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1996; 16():239-73. PubMed ID: 8639384
[No Abstract] [Full Text] [Related]
20. Biological response modifiers.
Clark JW
Cancer Chemother Biol Response Modif; 1993; 14():207-26. PubMed ID: 8312103
[No Abstract] [Full Text] [Related]
[Next] [New Search]
